Monoclonal antibodies in solid tumours

Area of Science:

• Oncology
• Immunotherapy
• Drug Development

Background:

• Monoclonal antibodies (mAbs) are key therapeutics for solid tumors.
• They target specific cell surface receptors or extracellular ligands involved in cancer progression.
• Approved mAbs include trastuzumab, cetuximab, panitumumab, bevacizumab, and catumaxomab for various cancers.

Purpose of the Study:

• To review current monoclonal antibody therapies for solid tumors.
• To discuss challenges and future directions in mAb development and application.
• To highlight the need for enhanced strategies in drug design and patient stratification.

Main Methods:

• Review of currently approved monoclonal antibodies for solid tumor treatment.
• Analysis of their mechanisms of action and clinical applications.
• Discussion of research and development efforts in the field.

Main Results:

• Several mAbs are approved and used for breast, colorectal, and lung cancers.
• Despite successes, challenges and disappointments persist in mAb therapy.
• Ongoing research focuses on improving efficacy and patient outcomes.

Conclusions:

• Monoclonal antibodies represent a significant advancement in solid tumor treatment.
• Future efforts must focus on intelligent compound design, biomarker discovery, and personalized medicine.
• Enhanced strategies are crucial for maximizing the therapeutic potential of mAbs.